Catalyst Pharmaceuticals (CPRX) Interest Expenses (2012 - 2026)

Catalyst Pharmaceuticals' Interest Expenses history runs 15 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Interest Expenses rose 24.97% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 24.97% YoY) and the FY2025 annual result came in at $30.5 million, down 1.78% from the prior year.
• Interest Expenses was $7.2 million for Q1 2026 at Catalyst Pharmaceuticals, up from $135000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $33.9 million in Q1 2023 and bottomed at -$368000.0 in Q4 2022.
• A 5-year average of $9.2 million and a median of $5.8 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 560.0% — and 2023, when it jumped 6221.97%.
• Catalyst Pharmaceuticals' Interest Expenses stood at -$368000.0 in 2022, then surged by 114.95% to $55000.0 in 2023, then surged by 70.91% to $94000.0 in 2024, then jumped by 43.62% to $135000.0 in 2025, then jumped by 5222.96% to $7.2 million in 2026.
• Business Quant data shows CPRX's Interest Expenses at $7.2 million in Q1 2026, $135000.0 in Q4 2025, and $5.8 million in Q3 2025.